Finance

A short seller is attacking cannabis company Tilray, saying the price of raw marijuana will 'come down aggressively'

Tilray CEO Brendan Kennedy
Tilray CEO Brendan Kennedy at the Nasdaq MarketSite. Tilray
Read in app

Marijuana producer Tilray sank on Monday after a hedge fund announced it opened up a short position in the company.

Chris Brown, a partner at the long-short firm Aristides Capital, said his firm is targeting Tilray at the Kase Learning Short Selling Conference in New York on Monday.

"This is definitely commodity business," Brown said, referring to the nascent marijuana industry. Brown said the price of raw marijuana would come down over time, and "come down aggressively."

The Nanaimo, British Columbia-based producer sank $6.55, or 2.7%, following Brown's presentation.

Tilray did not immediately respond to a request for comment.

Aphria, another Canadian marijuana producer, sank as much as $1.31, or 30%, before recovering slightly on Monday after short seller Gabriel Grego, the founder of Quintessential Capital Management, said the company was a "black hole" earlier at the conference.

Read more: Famous short seller Andrew Left is creating a cannabis fund. He explains why the market's not in a bubble, but does need to 'chill out.'

Tilray and other marijuana producers have been the target of short sellers before.

Andrew Left, who gained notoriety for shorting the pharmaceutical company Valeant, opened a short position in both Tilray and the marijuana producer Cronos Group in August through his firm, Citron Research.

Left is building out a fund to focus on long and short plays in the cannabis sector.

In October, TD Ameritrade warned retail investors to steer clear of the often volatile sector.

"The marijuana and cannabis industry — sometimes referred to as the Wild West of investing — is littered with high-flyers, potentially over-valued companies, and even scams," the stock brokerage firm said in a three-minute video posted on its Youtube account.

Bradley Saacks contributed reporting.

Read next

Jeremy is the founder and editor-in-chief of Cultivated Media, a newsletter bringing readers inside the emerging cannabis industry. Beyond his reporting, Jeremy is studying for his MBA at Columbia Business School and holds a certificate in cannabis pharmacology from the University of Vermont where he studied as a cannabis media fellow. Jeremy was formerly a senior reporter at Insider where he focused on the cannabis industryJeremy has covered the bumpy rollout of Canada's cannabis legalization, the boom in cannabis companies going public (and the resulting fallout), multibillion-dollar mergers between cannabis companies and corporations from other industries, the ongoing health effects from vaporizers, the mislabeling of CBD products, and how the world's largest financial, legal, and political institutions are reacting to and planning for legalization. He has also gotten scoops and broken news on layoffs affecting cannabis companies, startups raising money, banks and law firms building specialized cannabis practices, tracked which companies and individuals are profiting from cannabis, and profiled some of the top executives, investors, and leaders in the industry.He is a sought-after expert on cannabis business and policy, frequently speaking to the media and at industry conferences.